Wednesday, November 07, 2018

DermWire TV: Dupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness

FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma’s Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. The Skin Cancer Foundation’s 22nd annual Gala raises $600,000 to support the organization’s educational campaigns, community programs, and research initiatives.November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society has information at SweatHelp.org.

Watch Video

Thursday, October 25, 2018

DermWireTV: Updates from ASDS and ISHRS

The Annual meeting of the American Society for Dermatologic Surgery (ASDS) gathered experts in dermatologic surgery in Phoenix. Joel L. Cohen, MD and Shannon Humphrey, MD, who received the 2018 ASDS Award for Outstanding Service, discussed effective cosmetic consults. Diane Berson, MD addressed both medical and device-based approaches to managing acne. The 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) gathered leaders in hair restoration in Hollywood this month. Sharon Keene, MD spoke about the problem of hair loss in women. Nilofer Farjo, MB, ChB, BAO addressed evolving approaches to hair transplantation in patients with scalp psoriasis.

Watch Video

Tuesday, October 09, 2018

DermWireTV: FDA Approvals, Acne Insights, EPI Gets Cloderm

In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US may share a history of acne, but other data highlight the negative impact of acne on quality of life. EPI Health has acquired the rights to Cloderm Cream, 0.1% and its authorized generic from Promius Pharma, LLC.

Watch Video

Wednesday, September 26, 2018

DermWireTV: Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance

Nestle’s Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dollars, gaining the rights to EB-001A, the investigational botulinum neurotoxin type E formulation. EB-001A, currently in phase 2 trials, is characterized by a rapid onset of action of about 24 hours and a short duration of effect of about two to four weeks. Aclaris Therapeutics has been increasing its education to physicians, releasing a new video series featuring dermatologist Dr. Kavita Mariwala. Aclaris markets Eskata, the only product FDA approved for topical treatment of seborrheic keratosis or SK. Sebacia Microparticles are now FDA-cleared for use in the treatment of mild to moderate inflammatory acne.

Watch Video

Wednesday, September 05, 2018

DermWire TV: Altreno's Approval, Psoriasis Insights

Ortho Dermatologics’ Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for Duobrii Lotion for the topical treatment of plaque psoriasis. Only 10 percent of patients with psoriasis feel their condition is under control with their current treatment plans, results of the PlaquePsoriasis.com survey "Psoriasis in America 2018" show. Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to results from multidisciplinary research from the Perelman School of Medicine at the University of Pennsylvania. JW Pharmaceutical and LEO Pharma have signed a global licensing agreement for JW’s novel atopic dermatitis drug candidate JW1601.

Watch Video

Thursday, August 16, 2018

DermWireTV: Almirall/Allergan, LEO/Bayer Deals

Leo Pharma has agreed to acquire Bayer’s global prescription dermatology unit, and Almirall will acquire Allergan’s US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execute a successful strategy. Those are findings from a survey from eRelevance. The FDA has approved IV Poteligeo injection (Kyowa Kirin) for the treatment of adult patients with either relapsed or refractory mycosis fungoides or Sézary syndrome, after at least one prior systemic therapy.

Watch Video

Wednesday, August 01, 2018

DermWireTV: Medical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018

The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dermatology to network and learn in Las Vegas. The meeting, presented by The Dermatology Education Foundation, offered insights on acne, acne scarring, and new treatments like delafloxacin and ozenoxacin.

Watch Video

Wednesday, July 11, 2018

DermWire TV: BrightGuard Covers NYC, Galderma Uncovers Rosacea Burden, Dermira's Qbrexza Approved

BrightGuard dispensers have now been installed at 53 public pools and 11 beaches in various locations throughout metropolitan New York. The impact of rosacea can be significant for affected patients. According to survey results released last month by Galderma, 86% of patients with rosacea modify their behavior in attempts to manage disease symptoms, and more than half say the disease has impacted their work productivity. The FDA has approved Qbrexza cloth (glycopyrronium) from Dermira for the topical treatment of primary axillary hyperhidrosis in patients 9 years of age and older.

Watch Video

Thursday, June 28, 2018

DermWireTV: New eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership

eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to board certified physicians from the 4 core specialities and is focused on optimizing aesthetic outcomes. Doris Day, MD, Tina Alster, MD, Mary Lupo, MD, and Vic Narurkar, MD weigh in. Leo Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub are joining forces with Advancing Innovation in Dermatology.

Watch Video

Thursday, June 07, 2018

DermWire TV: Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk

A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TNF approved for psoriasis. There is now evidence that, like psoriasis and rosacea, eczema may be linked to cardiovascular risk. Spironolactone may be just as effective as antibiotics for the treatment of women with acne, researchers from the Perelman School of Medicine at the University of Pennsylvania report.

Watch Video

Thursday, May 24, 2018

DermWireTV: Sunscreen Ratings, Restylane Lyft for Hands, NPF, SCF News

Both Consumer Reports and the Environmental Working Group have issued sunscreen rankings, and while some products shine, many products may underperform. FDA issued warnings to several companies illegally marketing dietary supplements that make unproven drug claims about protecting consumers from sun exposure. Restylane Lyft has become the first hyaluronic acid filler to receive FDA approval for use on the dorsal hands of people older than 21. Jerry Bagel, MD will receive the Excellence in Leadership Award from the National Psoriasis Foundation next month. The Skin Cancer Foundation has kicked off the second year of its mobile education and screening program called Destination: Healthy Skin.

Watch Video

Thursday, May 10, 2018

DermWireTV: Skin Cancer Awareness, Epiduo Data, Impoyz Launch

Data shed light on patents’ attitudes towards kids’ sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis’ Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations. Data highlight clinical experience with Epiduo Forte Gel. Encore Dermatology launches Impoyz Cream.

Watch Video
Load More